Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edesa Biotech (EDSA) Current Deferred Revenue (2016 - 2019)

Edesa Biotech's Current Deferred Revenue history spans 5 years, with the latest figure at $80000.0 for Q1 2019.

  • For Q1 2019, Current Deferred Revenue changed N/A year-over-year to $80000.0; the TTM value through Mar 2019 reached $80000.0, changed N/A, while the annual FY2015 figure was $173333.0, N/A changed from the prior year.
  • Current Deferred Revenue for Q1 2019 was $80000.0 at Edesa Biotech, roughly flat from $80000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $173333.0 in Q2 2015 and bottomed at $80000.0 in Q4 2018.
  • The 4-year median for Current Deferred Revenue is $173333.0 (2015), against an average of $142222.0.
  • The largest YoY upside for Current Deferred Revenue was 0.0% in 2016 against a maximum downside of 0.0% in 2016.
  • A 4-year view of Current Deferred Revenue shows it stood at $173333.0 in 2015, then changed by 0.0% to $173333.0 in 2016, then plummeted by 53.85% to $80000.0 in 2018, then changed by 0.0% to $80000.0 in 2019.
  • Per Business Quant, the three most recent readings for EDSA's Current Deferred Revenue are $80000.0 (Q1 2019), $80000.0 (Q4 2018), and $173333.0 (Q2 2016).